Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» CNS
CNS
Brain drug developer Alto Neuroscience prices $129M IPO
BioPharma Dive
Fri, 02/2/24 - 11:39 am
Alto Neuroscience
IPOs
CNS
Sanofi Sells 11 CNS Assets to Pharmanovia including Frisium and Gardenal
BioSpace
Tue, 09/19/23 - 10:53 am
Sanofi
Pharmanovia
CNS
Frisium
Gardenal
Neurocrine blows fresh wind in Voyager's sails with $175M upfront for CNS capsid collab
Fierce Biotech
Mon, 01/9/23 - 10:34 am
Voyager Therapeutics
Neurocrine
capsids
CNS
Parkinson's Disease
CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic
Businesswire
Wed, 07/20/22 - 09:36 am
CAMP4
funding
CNS
Dravet syndrome
Sanofi offloads 17 brands to Neuraxpharm
Fierce Pharma
Tue, 07/12/22 - 10:57 am
Sanofi
CNS
Neuraxpharm
SciNeuro Pharmaceuticals Announces a License and Option Agreement with GSK to Progress Development of Novel Therapies for CNS Diseases
BioSpace
Wed, 06/1/22 - 09:46 am
SciNeuro
CNS
GSK
Alzheimer's disease
Sanofi Strikes Deal With Mysterious Psychedelics Biotech Terran
BioSpace
Thu, 04/21/22 - 11:27 pm
Sanofi
Terran Biosciences
CNS
psychedelic drugs
Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets
BioSpace
Thu, 04/21/22 - 10:54 am
Terran Biosciences
Sanofi
CNS
Chasing Bristol Myers and Biogen/Denali, CNS biotech raises $100M in dash toward clinic
Endpoints
Wed, 03/30/22 - 10:35 am
Neuron23
funding
CNS
Bristol Myers Squibb
Biogen
Denali
With a make-or-break PhIII readout looming, a struggling Concert offloads a 'portfolio' of drugs
Endpoints
Mon, 03/14/22 - 10:31 am
Concert Pharmaceuticals
Terran Biosciences
CNS
schizophrenia
Digging into biopharma’s big buyout areas
EP Vantage
Fri, 03/11/22 - 10:26 am
M&A
oncology
CNS
Rare Diseases
cancer
IACT LMC Manna Research Merges with True North Clinical Research, Boosting the Network’s Central Nervous System Disorder Capabilities
CP WIre
Mon, 12/20/21 - 12:30 pm
IACT Health
True North Clinical Research
R&D
M&A
IACT LMC Manna Research
CNS
Lundbeck taps Inscopix’ brain-mapping camera tech for CNS research
Pharmaforum
Mon, 09/20/21 - 10:59 pm
Lundbeck
Inscopix
CNS
R&D
Takeda fleshes out CNS pact with peptide drugmaker, setting aside $3.5B in future milestones
Endpoints
Tue, 07/27/21 - 10:31 am
Takeda
CNS
peptides
Japan
PeptiDream
In quick start to new year's M&A, Arvelle Therapeutics hands reins to Angelini as it nears EU approval for cenobamate
Endpoints
Mon, 01/4/21 - 10:41 am
Arvelle Therapeutics
Angelini Pharma
M&A
CNS
epilepsy
cenobamate
Axovant
Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B
Fierce Biotech
Wed, 10/14/20 - 10:49 am
Dyno
Roche
Spark Therapeutics
gene therapy
liver disease
CNS
Cyclerion fails sickle cell test, prompting pivot to CNS disease
Fierce Biotech
Wed, 10/14/20 - 10:46 am
Cyclerion
olinciguat
sickle cell disease
CNS
IW-6463
Evox’s exosome platform draws Lilly in potential $1.2B CNS deal
BioWorld
Tue, 06/9/20 - 11:09 am
Evox Therapeutics
Eli Lilly
exosomes
CNS
drug delivery
Taysha Launches With $30M to Bring Gene Therapy to CNS Disorders
Xconomy
Wed, 04/29/20 - 10:47 am
Taysha
gene therapy
CNS
AveXis
Cerevance Nabs $45 Million in Funding to Support CNS Disease Research
BioSpace
Tue, 04/14/20 - 10:08 pm
Cerevance
CNS
Alzheimer's disease
Parkinson's Disease
Pages
1
2
3
next ›
last »